Amfotericina B liposomiale nella terapia della leishmaniosi viscerale: Risultati di uno studio pilota su 98 pazienti immunocompetenti in eta pediatrica

Translated title of the contribution: Liposomal amphotericin B for treatment of visceral leishmaniasis: Results of a pilot study on 98 immunocompetent children

L. Di Martino, E. Castagnola, R. Giacchino, L. Tasso, S. Scotti, F. Raimondi, M. Pettoello Mantovani, A. Cascio, L. Gradoni, A. Scalone, R. N. Davidson

Research output: Contribution to journalArticle

Abstract

Liposomal amphotericin B was administered as treatment of visceral leishmaniasis to 98 immunocompetent children according to different schedules: 11 were treated with a total dose of 21 mg/kg, 13 (8 first diagnoses and 5 relapses) with a total dose of 30 mg/kg, 63 with a total dose of 18 mg/kg and 16 with a total dose of 15 mg/kg. Five episodes of relapse were observed within 4 months after the end of treatment: 1 in the group treated with 18 mg/kg and 4 in the group treated with 15 mg/kg. All relapses were treated successfully with a total dose of 30 mg/kg. The only side effects reported was ipokalemia in 24/103 (23%) administered cycles. In conclusion liposomal amphotericin B is effective and safe for treatment of visceral leishmania in immunocompetent children.

Original languageItalian
Pages (from-to)241-244
Number of pages4
JournalRivista Italiana di Pediatria
Volume23
Issue number2
Publication statusPublished - Apr 1997

Fingerprint

Visceral Leishmaniasis
Recurrence
Leishmania
Appointments and Schedules
Therapeutics
liposomal amphotericin B

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Amfotericina B liposomiale nella terapia della leishmaniosi viscerale : Risultati di uno studio pilota su 98 pazienti immunocompetenti in eta pediatrica. / Di Martino, L.; Castagnola, E.; Giacchino, R.; Tasso, L.; Scotti, S.; Raimondi, F.; Pettoello Mantovani, M.; Cascio, A.; Gradoni, L.; Scalone, A.; Davidson, R. N.

In: Rivista Italiana di Pediatria, Vol. 23, No. 2, 04.1997, p. 241-244.

Research output: Contribution to journalArticle

Di Martino, L, Castagnola, E, Giacchino, R, Tasso, L, Scotti, S, Raimondi, F, Pettoello Mantovani, M, Cascio, A, Gradoni, L, Scalone, A & Davidson, RN 1997, 'Amfotericina B liposomiale nella terapia della leishmaniosi viscerale: Risultati di uno studio pilota su 98 pazienti immunocompetenti in eta pediatrica', Rivista Italiana di Pediatria, vol. 23, no. 2, pp. 241-244.
Di Martino, L. ; Castagnola, E. ; Giacchino, R. ; Tasso, L. ; Scotti, S. ; Raimondi, F. ; Pettoello Mantovani, M. ; Cascio, A. ; Gradoni, L. ; Scalone, A. ; Davidson, R. N. / Amfotericina B liposomiale nella terapia della leishmaniosi viscerale : Risultati di uno studio pilota su 98 pazienti immunocompetenti in eta pediatrica. In: Rivista Italiana di Pediatria. 1997 ; Vol. 23, No. 2. pp. 241-244.
@article{eaf1580db1b54589b68f6c34e0e2a3b6,
title = "Amfotericina B liposomiale nella terapia della leishmaniosi viscerale: Risultati di uno studio pilota su 98 pazienti immunocompetenti in eta pediatrica",
abstract = "Liposomal amphotericin B was administered as treatment of visceral leishmaniasis to 98 immunocompetent children according to different schedules: 11 were treated with a total dose of 21 mg/kg, 13 (8 first diagnoses and 5 relapses) with a total dose of 30 mg/kg, 63 with a total dose of 18 mg/kg and 16 with a total dose of 15 mg/kg. Five episodes of relapse were observed within 4 months after the end of treatment: 1 in the group treated with 18 mg/kg and 4 in the group treated with 15 mg/kg. All relapses were treated successfully with a total dose of 30 mg/kg. The only side effects reported was ipokalemia in 24/103 (23{\%}) administered cycles. In conclusion liposomal amphotericin B is effective and safe for treatment of visceral leishmania in immunocompetent children.",
keywords = "Liposomal Amphotencin B, Pediatrics, Visceral leishmaniasis",
author = "{Di Martino}, L. and E. Castagnola and R. Giacchino and L. Tasso and S. Scotti and F. Raimondi and {Pettoello Mantovani}, M. and A. Cascio and L. Gradoni and A. Scalone and Davidson, {R. N.}",
year = "1997",
month = "4",
language = "Italian",
volume = "23",
pages = "241--244",
journal = "Rivista Italiana di Pediatria",
issn = "0392-5161",
publisher = "Pacini Editore s.r.l.",
number = "2",

}

TY - JOUR

T1 - Amfotericina B liposomiale nella terapia della leishmaniosi viscerale

T2 - Risultati di uno studio pilota su 98 pazienti immunocompetenti in eta pediatrica

AU - Di Martino, L.

AU - Castagnola, E.

AU - Giacchino, R.

AU - Tasso, L.

AU - Scotti, S.

AU - Raimondi, F.

AU - Pettoello Mantovani, M.

AU - Cascio, A.

AU - Gradoni, L.

AU - Scalone, A.

AU - Davidson, R. N.

PY - 1997/4

Y1 - 1997/4

N2 - Liposomal amphotericin B was administered as treatment of visceral leishmaniasis to 98 immunocompetent children according to different schedules: 11 were treated with a total dose of 21 mg/kg, 13 (8 first diagnoses and 5 relapses) with a total dose of 30 mg/kg, 63 with a total dose of 18 mg/kg and 16 with a total dose of 15 mg/kg. Five episodes of relapse were observed within 4 months after the end of treatment: 1 in the group treated with 18 mg/kg and 4 in the group treated with 15 mg/kg. All relapses were treated successfully with a total dose of 30 mg/kg. The only side effects reported was ipokalemia in 24/103 (23%) administered cycles. In conclusion liposomal amphotericin B is effective and safe for treatment of visceral leishmania in immunocompetent children.

AB - Liposomal amphotericin B was administered as treatment of visceral leishmaniasis to 98 immunocompetent children according to different schedules: 11 were treated with a total dose of 21 mg/kg, 13 (8 first diagnoses and 5 relapses) with a total dose of 30 mg/kg, 63 with a total dose of 18 mg/kg and 16 with a total dose of 15 mg/kg. Five episodes of relapse were observed within 4 months after the end of treatment: 1 in the group treated with 18 mg/kg and 4 in the group treated with 15 mg/kg. All relapses were treated successfully with a total dose of 30 mg/kg. The only side effects reported was ipokalemia in 24/103 (23%) administered cycles. In conclusion liposomal amphotericin B is effective and safe for treatment of visceral leishmania in immunocompetent children.

KW - Liposomal Amphotencin B

KW - Pediatrics

KW - Visceral leishmaniasis

UR - http://www.scopus.com/inward/record.url?scp=0030877366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030877366&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0030877366

VL - 23

SP - 241

EP - 244

JO - Rivista Italiana di Pediatria

JF - Rivista Italiana di Pediatria

SN - 0392-5161

IS - 2

ER -